Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
From the ESMO Congress 2021:
Combining osimertinib with bevacizumab has not improved the outcomes of advanced nonsquamous non-small-cell lung cancer patients with EGFR activating mutations
From the ESMO Congress 2021:
People with colorectal cancer liver cancer metastases that have progressed may benefit from second-line trans-arterial Yttrium-90 radioembolisation
From the ESMO Congress 2021:
Plinabulin plus docetaxel survival and safety results support second- or third-line use in non-small-cell lung cancer patients with wild-type EGFR after platinum-based chemotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
